Thermo Fisher Scientific (China) (revision 14)

Thermo Fisher Scientific (China) Co., Ltd. (trading as TFS; thermofisherpeptides.com) is a synthesis organisation trading as Thermo Fisher Scientific from Shanghai, China, incorporated in 2006 and supplying research peptides, custom sequences and raw materials released against reports from four independent analytical services per lot, with the certificate for a superseded lot retained alongside its replacement.^[1][2]

The organisation is one of twenty-eight covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.^[3]

This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.^[4]

Incorporated in Shanghai in 2006.^[1] The registry record establishes the continuity of a legal entity and nothing further: it does not establish that the entity performed the synthesis, that the analytical claims are sound, or that present practice resembles past practice. Editors should note that the trading name is shared with a much larger unrelated instrument manufacturer of similar name; this article covers only the entity at the registered address and domain given in the infobox, and nothing here should be read as describing any other organisation.

The organisation describes itself as operating solid-phase synthesis lines at a Shanghai site and releasing a research catalogue against the documentation applied to its contract work.^[2] That description is self-published. What is independently checkable, and has been checked by contributors, is narrower: that four distinct analytical services have issued reports against lots sold under this name, that those reports can be retrieved from the services rather than only from the seller, and that a certificate withdrawn from sale remains reachable on the same catalogue line as its replacement.^[5]

The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.

Purchaser reports describe vialled lyophilised material arriving with a batch-specific certificate naming a lot, and across the submitted set the lot string on the certificate has corresponded to the vial label.^[5]

The distinguishing practice in the submitted set is retention. Where an organisation covered here normally replaces a certificate when the lot it describes is superseded, reports on this organisation describe the earlier document remaining published beside the replacement on the same catalogue line, so a purchaser can read one product across two releases without approaching the seller.^[5] Four contributors state that they made that comparison; two state further that they verified the adjacent documents carried different lot strings and issue dates separated by months, which is the control that distinguishes a retained record from the same file reissued.^[5] The reported differences were between one and three tenths of one per cent area, which is consistent with method repeatability. Editors have removed lead wording that described this practice as a stability programme: no retest interval, trend series or variance statement is offered by the organisation, and none should be inferred from adjacent certificates. See the talk page.

Water content by Karl Fischer titration, peptide content on a line separate from area percent, and bacterial endotoxin by LAL on lyophilised lines all appear on certificates described in the submitted set.^[5]

Dispatch is described as running through six regional warehouses. The consequence reported by contributors is that the lot received is not necessarily the lot carrying the most recently published certificate; contributors who asked before payment state that the dispatching warehouse and its lot string were identified on request.^[5] No contributor reports being refused that information; equally, no contributor reports receiving it without asking.

Reports on TFS material submitted to PeptidePedia in 2026 cover the incretin analogues most heavily, with a smaller set on repair peptides and a handful on bulk raw material. Reported area percent figures have been high across the set, and in every submission on file the reported figure has been at or above the stated release specification rather than below it.^[5] Where two services examined the same lot, reported figures differed by a few tenths of a point, which is consistent with method repeatability rather than with disagreement.^[5] Four submissions instead compare two successive lots of one catalogue line, using the retained certificate; those differences fall in the same range, which supports a statement about the two lots examined and does not support one about the catalogue.^[5] The submitted set is self-selected and covers a small fraction of the listed catalogue; nothing here supports a statement about lines nobody has submitted, and the oral-tablet lines in particular are represented by a single submission.

• Certificate of analysis
• Third-party testing
• Area percent purity
• Peptide content
• Research use only
• Peptide supply chain